GILEAD SCIENCES, INC. (GILD) FY2024 Q1 P&L / Income Statement

Income StatementCash FlowBalance Sheet

Revenue by Product and Service by Geography

2024-01-01 to 2024-03-31

Swipe to see the full flow
GILEAD SCIENCES, INC. (GILD) FY2024 Q1 P&L / Income StatementIncome statement for 2024-01-01 through 2024-03-31. View: Product and Service by Geographical. Revenue uses this breakdown; costs and expenses retain the consolidated categories.SOURCESREVENUE RECONCILIATIONREVENUEGROSSOPERATINGPRE-TAXNETProduct sales - UNITED STATESTotal HIV - UNITED STATESBiktarvy - UNITED STATESProduct sales - EuropeProduct sales - Rest of WorldTotal HIV - EuropeTotal Oncology - UNITED STATESTotal Liver Disease - UNITED STATESDescovy - UNITED STATESBiktarvy - EuropeTotal HIV - Rest of WorldGenvoya - UNITED STATESVeklury - UNITED STATESBiktarvy - Rest of WorldTotal Oncology - EuropeSofosbuvir/Velpatasvir - UNITED STATESTotal Cell Therapy - UNITED STATESOdefsey - UNITED STATESTotal Liver Disease - Rest of WorldTrodelvy - UNITED STATESTotal Cell Therapy - EuropeYescarta - UNITED STATESVeklury - Rest of WorldYescarta - EuropeTotal Liver Disease - EuropeVemlidy - Rest of WorldRevenue share - Symtuza - UNITED STATESTotal Oncology - Rest of WorldVemlidy - UNITED STATESSofosbuvir/Velpatasvir - EuropeTotal Other - EuropeSofosbuvir/Velpatasvir - Rest of WorldOdefsey - EuropeTotal Other - UNITED STATESTotal Other - Rest of WorldAmBisome - EuropeVeklury - EuropeTrodelvy - EuropeTotal Cell Therapy - Rest of WorldAmBisome - Rest of WorldTecartus - UNITED STATESYescarta - Rest of WorldGenvoya - EuropeTecartus - EuropeTrodelvy - Rest of WorldRevenue share - Symtuza - EuropeDescovy - Rest of WorldDescovy - EuropeRoyalty, contract and other revenues - UNITED STATESGenvoya - Rest of WorldRoyalty, contract and other revenues - EuropeAmBisome - UNITED STATESOdefsey - Rest of WorldVemlidy - EuropeTecartus - Rest of WorldRevenue share - Symtuza - Rest of WorldRoyalty, contract and other revenues - Rest of WorldOther HIV - UNITED STATESOther - UNITED STATESOther Liver Disease - EuropeOther HIV - EuropeOther Liver Disease - UNITED STATESOther Liver Disease - Rest of WorldOther HIV - Rest of WorldOther - Rest of WorldOther - EuropeTotal revenuesRevenue before reconciliation (calculated)Components above reported revenue (calculated)Gross profit (calculated)Cost of goods soldOperating (loss) incomeOperating expenses (calculated)Acquired in-process research and development expensesIn-process research and development impairmentResearch and development expensesSelling, general and administrative expenses(Loss) income before income taxesOther income (expense), net (calculated)Net (loss) incomeIncome tax (benefit) expenseRevenue before reconciliation (calculated)Revenue beforereconciliation(calculated)$19.90 BGross profit (calculated)Gross profit(calculated)$5.13 BOperating (loss) incomeOperating(loss) income−$4.32 B(Loss) income before income taxes(Loss) incomebefore income taxes−$4.49 BTotal revenuesTotal revenues$6.69 BNet (loss) incomeNet (loss) income−$4.17 BProduct sales - UNITED STATESProduct sales - UNITED STATES$4.61 BOperating expenses (calculated)Operating expenses(calculated)$9.46 BTotal HIV - UNITED STATESTotal HIV - UNITED STATES$3.41 BCost of goods soldCost of goods sold$1.55 BIncome tax (benefit) expenseIncome tax(benefit) expense−$315.00 MAcquired in-process research and development expensesAcquired in-process researchand development expenses$4.13 BBiktarvy - UNITED STATESBiktarvy - UNITED STATES$2.32 BProduct sales - EuropeProduct sales - Europe$1.14 BIn-process research and development impairmentIn-process research anddevelopment impairment$2.43 BProduct sales - Rest of WorldProduct sales - Rest of World$894.00 MResearch and development expensesResearch anddevelopment expenses$1.52 BTotal HIV - EuropeTotal HIV - Europe$596.00 MOther income (expense), net (calculated)Other income,net (calculated)−$164.00 MSelling, general and administrative expensesSelling, general andadministrative expenses$1.38 BComponents above reported revenue (calculated)Components abovereported revenue(calculated)−$13.22 BTotal Oncology - UNITED STATESTotal Oncology - UNITED STATES$431.00 MTotal Liver Disease - UNITED STATESTotal Liver Disease - UNITED STATES$385.00 MDescovy - UNITED STATESDescovy - UNITED STATES$371.00 MBiktarvy - EuropeBiktarvy - Europe$365.00 MTotal HIV - Rest of WorldTotal HIV - Rest of World$342.00 MGenvoya - UNITED STATESGenvoya - UNITED STATES$332.00 MVeklury - UNITED STATESVeklury - UNITED STATES$315.00 MBiktarvy - Rest of WorldBiktarvy - Rest of World$265.00 MTotal Oncology - EuropeTotal Oncology - Europe$262.00 MSofosbuvir/Velpatasvir - UNITED STATESSofosbuvir/Velpatasvir- UNITED STATES$248.00 MTotal Cell Therapy - UNITED STATESTotal Cell Therapy - UNITED STATES$225.00 MOdefsey - UNITED STATESOdefsey - UNITED STATES$223.00 MTotal Liver Disease - Rest of WorldTotal Liver Disease - Rest of World$215.00 MTrodelvy - UNITED STATESTrodelvy - UNITED STATES$206.00 MTotal Cell Therapy - EuropeTotal Cell Therapy - Europe$195.00 MYescarta - UNITED STATESYescarta - UNITED STATES$170.00 MVeklury - Rest of WorldVeklury - Rest of World$169.00 MYescarta - EuropeYescarta - Europe$158.00 MTotal Liver Disease - EuropeTotal Liver Disease - Europe$137.00 MVemlidy - Rest of WorldVemlidy - Rest of World$119.00 MRevenue share - Symtuza - UNITED STATESRevenue share - Symtuza- UNITED STATES$104.00 MTotal Oncology - Rest of WorldTotal Oncology - Rest of World$96.00 MVemlidy - UNITED STATESVemlidy - UNITED STATES$95.00 MSofosbuvir/Velpatasvir - EuropeSofosbuvir/Velpatasvir - Europe$79.00 MTotal Other - EuropeTotal Other - Europe$79.00 MSofosbuvir/Velpatasvir - Rest of WorldSofosbuvir/Velpatasvir- Rest of World$78.00 MOdefsey - EuropeOdefsey - Europe$76.00 MTotal Other - UNITED STATESTotal Other - UNITED STATES$73.00 MTotal Other - Rest of WorldTotal Other - Rest of World$71.00 MAmBisome - EuropeAmBisome - Europe$70.00 MVeklury - EuropeVeklury - Europe$70.00 MTrodelvy - EuropeTrodelvy - Europe$68.00 MTotal Cell Therapy - Rest of WorldTotal Cell Therapy - Rest of World$60.00 MAmBisome - Rest of WorldAmBisome - Rest of World$60.00 MTecartus - UNITED STATESTecartus - UNITED STATES$55.00 MYescarta - Rest of WorldYescarta - Rest of World$52.00 MGenvoya - EuropeGenvoya - Europe$49.00 MTecartus - EuropeTecartus - Europe$36.00 MTrodelvy - Rest of WorldTrodelvy - Rest of World$36.00 MRevenue share - Symtuza - EuropeRevenue share - Symtuza - Europe$33.00 MDescovy - Rest of WorldDescovy - Rest of World$29.00 MDescovy - EuropeDescovy - Europe$26.00 MRoyalty, contract and other revenues - UNITED STATESRoyalty, contract and otherrevenues - UNITED STATES$23.00 MGenvoya - Rest of WorldGenvoya - Rest of World$21.00 MRoyalty, contract and other revenues - EuropeRoyalty, contract andother revenues - Europe$15.00 MAmBisome - UNITED STATESAmBisome - UNITED STATES$14.00 MOdefsey - Rest of WorldOdefsey - Rest of World$11.00 MVemlidy - EuropeVemlidy - Europe$11.00 MTecartus - Rest of WorldTecartus - Rest of World$8.00 MRevenue share - Symtuza - Rest of WorldRevenue share -Symtuza - Rest of World$3.00 MRoyalty, contract and other revenues - Rest of WorldRoyalty, contract and otherrevenues - Rest of World$1.00 MOther HIV - UNITED STATESOther HIV - UNITED STATES$60.00 MOther - UNITED STATESOther - UNITED STATES$59.00 MOther Liver Disease - EuropeOther Liver Disease - Europe$47.00 MOther HIV - EuropeOther HIV - Europe$45.00 MOther Liver Disease - UNITED STATESOther Liver Disease - UNITED STATES$42.00 MOther Liver Disease - Rest of WorldOther Liver Disease - Rest of World$19.00 MOther HIV - Rest of WorldOther HIV - Rest of World$12.00 MOther - Rest of WorldOther - Rest of World$12.00 MOther - EuropeOther - Europe$9.00 M
Chart details

GILEAD SCIENCES, INC. (GILD) FY2024 Q1 P&L / Income Statement

Income statement for 2024-01-01 through 2024-03-31. View: Product and Service by Geographical. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Total revenues
6,686,000,000 US dollars
Cost of goods sold
1,552,000,000 US dollars
Gross profit (calculated)
5,134,000,000 US dollars
Operating expenses (calculated)
9,456,000,000 US dollars
Operating (loss) income
negative 4,322,000,000 US dollars
Other income (expense), net (calculated)
negative 164,000,000 US dollars
(Loss) income before income taxes
negative 4,486,000,000 US dollars
Income tax (benefit) expense
negative 315,000,000 US dollars
Net (loss) income
negative 4,170,000,000 US dollars
Tecartus - UNITED STATES
55,000,000 US dollars
Tecartus - Rest of World
8,000,000 US dollars
Tecartus - Europe
36,000,000 US dollars
Total Cell Therapy - UNITED STATES
225,000,000 US dollars
Total Cell Therapy - Rest of World
60,000,000 US dollars
Total Cell Therapy - Europe
195,000,000 US dollars
Yescarta - UNITED STATES
170,000,000 US dollars
Yescarta - Rest of World
52,000,000 US dollars
Yescarta - Europe
158,000,000 US dollars
Total HIV - UNITED STATES
3,405,000,000 US dollars
Total HIV - Rest of World
342,000,000 US dollars
Total HIV - Europe
596,000,000 US dollars
Biktarvy - UNITED STATES
2,315,000,000 US dollars
Biktarvy - Rest of World
265,000,000 US dollars
Biktarvy - Europe
365,000,000 US dollars
Descovy - UNITED STATES
371,000,000 US dollars
Descovy - Rest of World
29,000,000 US dollars
Descovy - Europe
26,000,000 US dollars
Genvoya - UNITED STATES
332,000,000 US dollars
Genvoya - Rest of World
21,000,000 US dollars
Genvoya - Europe
49,000,000 US dollars
Odefsey - UNITED STATES
223,000,000 US dollars
Odefsey - Rest of World
11,000,000 US dollars
Odefsey - Europe
76,000,000 US dollars
Other HIV - UNITED STATES
60,000,000 US dollars
Other HIV - Rest of World
12,000,000 US dollars
Other HIV - Europe
45,000,000 US dollars
Revenue share - Symtuza - UNITED STATES
104,000,000 US dollars
Revenue share - Symtuza - Rest of World
3,000,000 US dollars
Revenue share - Symtuza - Europe
33,000,000 US dollars
Total Liver Disease - UNITED STATES
385,000,000 US dollars
Total Liver Disease - Rest of World
215,000,000 US dollars
Total Liver Disease - Europe
137,000,000 US dollars
Other Liver Disease - UNITED STATES
42,000,000 US dollars
Other Liver Disease - Rest of World
19,000,000 US dollars
Other Liver Disease - Europe
47,000,000 US dollars
Sofosbuvir/Velpatasvir - UNITED STATES
248,000,000 US dollars
Sofosbuvir/Velpatasvir - Rest of World
78,000,000 US dollars
Sofosbuvir/Velpatasvir - Europe
79,000,000 US dollars
Vemlidy - UNITED STATES
95,000,000 US dollars
Vemlidy - Rest of World
119,000,000 US dollars
Vemlidy - Europe
11,000,000 US dollars
Total Oncology - UNITED STATES
431,000,000 US dollars
Total Oncology - Rest of World
96,000,000 US dollars
Total Oncology - Europe
262,000,000 US dollars
AmBisome - UNITED STATES
14,000,000 US dollars
AmBisome - Rest of World
60,000,000 US dollars
AmBisome - Europe
70,000,000 US dollars
Other - UNITED STATES
59,000,000 US dollars
Other - Rest of World
12,000,000 US dollars
Other - Europe
9,000,000 US dollars
Total Other - UNITED STATES
73,000,000 US dollars
Total Other - Rest of World
71,000,000 US dollars
Total Other - Europe
79,000,000 US dollars
Royalty, contract and other revenues - UNITED STATES
23,000,000 US dollars
Royalty, contract and other revenues - Rest of World
1,000,000 US dollars
Royalty, contract and other revenues - Europe
15,000,000 US dollars
Trodelvy - UNITED STATES
206,000,000 US dollars
Trodelvy - Rest of World
36,000,000 US dollars
Trodelvy - Europe
68,000,000 US dollars
Veklury - UNITED STATES
315,000,000 US dollars
Veklury - Rest of World
169,000,000 US dollars
Veklury - Europe
70,000,000 US dollars
Product sales - UNITED STATES
4,609,000,000 US dollars
Product sales - Rest of World
894,000,000 US dollars
Product sales - Europe
1,144,000,000 US dollars
Selling, general and administrative expenses
1,375,000,000 US dollars
Acquired in-process research and development expenses
4,131,000,000 US dollars
Research and development expenses
1,520,000,000 US dollars
In-process research and development impairment
2,430,000,000 US dollars
Revenue before reconciliation (calculated)
19,903,000,000 US dollars. Sum of the reported revenue categories before the separately reported reconciliation.
Components above reported revenue (calculated)
negative 13,217,000,000 US dollars. The disclosed components add up to more than reported revenue; this is the difference, calculated, not a reported item.

Chart connections

  • Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
  • Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
  • Reported revenue categories plus the separately reported signed reconciliation equals consolidated revenue.
  • The amounts that make up net income come to −$4,171.00 M and net income is −$4,170.00 M; the $1.00 M difference is within the rounding of the filed amounts.
GILEAD SCIENCES, INC. (GILD) FY2024 Q1 P&L / Income Statement Sankey chart, Product and service — Product and Service by Geographical view
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Gross margin

76.8%

Gross profit / revenue

Operating margin

−64.6%

Operating profit / revenue

Newsletter

Get the teardowns by email

Subscribe if you want the public-company teardowns in your inbox when they're released.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!